Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by 4D Molecular Therapeutics, Inc.

< Previous 1 2 3 Next >
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.